Skip to content

FDA Requires a Warning About Rare Vision Loss (NAION) on All GLP-1 Drugs, From Ozempic and Wegovy to Mounjaro and Zepbound

November 10, 2026 · 7 min

Show notes

On November 9, 2026, the US Food and Drug Administration said it is requiring the makers of all GLP-1 receptor agonist medicines, including Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound and Foundayo, to add information to the Warnings and Precautions section of their labels about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that can cause sudden, painless vision loss in one eye, including permanent vision loss. In an FDA analysis of 126 randomized trials with 134,253 patients, there were 10 probable NAION cases among people on GLP-1 drugs and 5 among people on placebo, or 6.4 versus 3.8 cases per 100,000 person-years. An FDA Sentinel study in adults with type 2 diabetes found a higher risk with GLP-1 drugs than with DPP-4 inhibitors but no statistically significant difference compared with SGLT2 inhibitors, and FDA's review of animal data did not identify a mechanism. FDA describes the risk as potential. We also cover the 2024 JAMA Ophthalmology study that prompted FDA's review, the European Medicines Agency's June 2025 conclusion that NAION is a very rare side effect of semaglutide, and statements from Novo Nordisk and Eli Lilly.

Sources

  • FDA Drug Safety Communication (Nov 9, 2026), labeling changes for GLP-1 receptor agonists due to potential increased risk of NAION: fda.gov
  • Reuters (Nov 9, 2026), US FDA orders new eye risk warnings for Ozempic, Zepbound: investing.com
  • Bloomberg (Nov 9, 2026), FDA adds warning label to obesity drugs for eye condition, with Novo Nordisk and Lilly statements: ndtvprofit.com
  • Healio (Nov 9, 2026), FDA to require NAION risk warning for GLP-1 therapies: healio.com
  • European Medicines Agency (June 6, 2025), PRAC concludes NAION is a very rare side effect of semaglutide medicines: ema.europa.eu
  • JAMA Ophthalmology (2024), Hathaway et al., risk of NAION in patients prescribed semaglutide (PubMed abstract): pubmed.ncbi.nlm.nih.gov

Cover: original code-generated illustration (no photo).

This episode is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication.

Visit glp1newspaper.com for today's stories and free email alerts.

All episodes of GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.